Why Replimune Group Inc (REPL) Stock Is Rising
As of 2026-08-26, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 25.52%. Featured in our EPS revision report on 2026-04-22.
Why REPL Stock Is Rising
- ·Current-Year Growth: Projected at 18.01%, supporting the forward estimate revision.
News Context
The primary structural driver is the upward revision to next-year EPS growth estimates, now at 29.89%. Recent headlines, however, are dominated by the FDA rejection and layoffs, with no earnings beat, contract win, or guidance raise to explain the move. The stock’s rise is not clearly supported by these negative catalysts, so any continued momentum appears disconnected from the fundamental news flow.
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 25.52%
- EPS growth this year
- 18.01%
- EPS next quarter (est)
- -$0.75
- Last price
- $15.09
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 25.52% | 18.01% | -$0.75 | $15.09 |
| 2026-08-25 | 29.89% | 15.30% | -$0.79 | $15.80 |
| 2026-08-24 | 29.89% | 15.30% | -$0.79 | $14.71 |
| 2026-08-23 | 29.89% | 15.30% | -$0.79 | $14.77 |
| 2026-08-21 | 29.89% | 15.30% | -$0.79 | $14.77 |
| 2026-08-20 | 29.89% | 15.30% | -$0.79 | $14.05 |
| 2026-08-16 | 25.51% | 13.02% | -$0.78 | $14.97 |
| 2026-08-14 | 31.58% | 15.83% | -$0.76 | $14.97 |
| 2026-08-13 | 31.21% | 18.00% | -$0.69 | $15.19 |
| 2026-08-12 | 31.21% | 18.00% | -$0.69 | $15.24 |
| 2026-08-11 | 31.21% | 18.00% | -$0.69 | $13.65 |
| 2026-08-10 | 31.21% | 18.00% | -$0.69 | $13.67 |
| 2026-08-09 | 31.21% | 18.00% | -$0.69 | $12.06 |
| 2026-08-07 | 31.21% | 18.00% | -$0.69 | $12.06 |
| 2026-08-06 | 33.75% | 28.15% | -$0.64 | $12.86 |
| 2026-08-05 | 33.75% | 28.15% | -$0.64 | $11.83 |
| 2026-08-04 | 33.75% | 28.15% | -$0.64 | $11.92 |
| 2026-08-03 | 31.72% | 28.20% | -$0.64 | $11.91 |
| 2026-08-02 | 31.72% | 28.20% | -$0.64 | $11.20 |
| 2026-07-31 | 31.72% | 28.20% | -$0.64 | $11.20 |
| 2026-07-30 | 27.41% | 30.77% | -$0.61 | $5.40 |
| 2026-07-29 | 27.41% | 30.77% | -$0.61 | $5.41 |
| 2026-07-28 | 27.41% | 30.77% | -$0.61 | $5.35 |
| 2026-07-27 | 27.41% | 30.77% | -$0.61 | $8.63 |
| 2026-07-26 | 27.41% | 30.77% | -$0.61 | $9.70 |
| 2026-07-24 | 27.41% | 30.77% | -$0.61 | $9.70 |
| 2026-07-23 | 27.41% | 30.77% | -$0.61 | $10.46 |
| 2026-07-22 | 32.27% | 30.77% | -$0.61 | $10.75 |
| 2026-07-21 | 36.80% | 35.13% | -$0.63 | $11.00 |
| 2026-07-20 | 36.80% | 35.13% | -$0.63 | $10.51 |
Reports Featuring REPL
Recent News
- Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.Barrons.com
- Replimune melanoma therapy rejected by FDA, shares plungeProactive
- FDA issues complete response letter to Replimunes RP1 for melanomaPharmaceutical Technology
- Replimune sinks 57% on second FDA rejection of melanoma drug; stock downgradedInvesting.com
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewswire
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
- Replimune Stock Tumbles After FDA Rejects Skin Cancer Therapy for Second TimeBarrons.com
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Replimune Group Inc (REPL) stock go up recently?▾
Replimune Group Inc (REPL) stock has risen following an analyst upgrade of its next-year EPS growth estimate on 2026-08-20. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Replimune Group Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Replimune Group Inc (REPL) has a next-year EPS growth estimate of 25.52%, based on analyst consensus.
When was the latest EPS estimate revision for REPL?▾
The most recent revision occurred on 2026-08-26, when analysts adjusted the next-year EPS growth estimate from 29.89% to 25.52%.
What sector and industry does Replimune Group Inc belong to?▾
Replimune Group Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. REPL appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Replimune Group Inc (REPL) appears here because it was detected by our daily top-EPS-revision-performer screen.